Refine
Has Fulltext
- yes (41)
Year of publication
Document Type
- Journal article (39)
- Book (2)
Language
- English (41) (remove)
Keywords
- Fabry disease (4)
- consortium (4)
- genetic modifiers (3)
- investigators (3)
- Box-Jenkins-Verfahren (2)
- Box–Jenkins Program (2)
- Fabry nephropathy (2)
- Frequency Domain (2)
- SAS <Programm> (2)
- State-Space Models (2)
- Time Series Analysis (2)
- Zeitreihenanalyse (2)
- Zustandsraummodelle (2)
- anxiety (2)
- cardiomyopathy (2)
- chronic kidney disease (2)
- common variants (2)
- education (2)
- genome-wide association (2)
- hypertrophic cardiomyopathy (2)
- ischemic stroke (2)
- modifiers (2)
- ovarian cancer (2)
- prospective (2)
- radiotherapy (2)
- single-nucleotide polymorphisms (2)
- survival (2)
- susceptibility loci (2)
- A-delta fibers (1)
- ALS treatment (1)
- Alpha-Galactosidase (1)
- Alzheimer’s disease (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anderson-Fabry Disease (1)
- BRCA1/2 (1)
- CRISPR-Cas Systems (1)
- CXCL10 (1)
- Cardiac dysfunction| Brain natriuretic peptide (1)
- Cimex lectularius (1)
- D313Y genotype (1)
- DNA (1)
- DNA damage (1)
- DNA double strand breaks (1)
- DNA methylation (1)
- Enzyme replacement therapy (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Fabry cardiomyopathy (1)
- Fabry patient (1)
- Fabry-associated pain (1)
- Galactosidase-A gene (1)
- Genotype–phenotype correlations (1)
- Heart failure (1)
- Histologic grade (1)
- IFNG (1)
- Induced Pluripotent Stem Cells (1)
- K-region (1)
- Kidney function (1)
- LV mass (1)
- Lag time (1)
- MTB (1)
- Male breast cancer (1)
- NEIL2 (1)
- Natural-history data (1)
- OGG1 (1)
- Outcome survey (1)
- Ovarian (1)
- Pain (1)
- Pain-related evoked potentials (1)
- Pathology (1)
- QuantiFERON\(^®\)-TB Gold Plus (1)
- RESP model (1)
- RT-qPCR (1)
- Racial differences (1)
- STS (1)
- Small fiber neuropathy (1)
- Stroke (1)
- T-Track\(^®\) TB (1)
- TB (1)
- Troponin (1)
- VEMP (1)
- ZNF365 (1)
- [18F]FDG-PET-CT (1)
- \(\gamma\)h2ax (1)
- abdominal lymph node metastases (1)
- accuracy (1)
- active TB (1)
- alleles (1)
- alpha/delta agonist GFT505 (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anticoagulation (1)
- assistive devices (1)
- astrogliosis (1)
- atherogenic dyslipidaemia (1)
- atrial fibrillation (1)
- bed bug (1)
- biomarkers (1)
- biosynthesis (1)
- blended learning (1)
- blood lymphocytes (1)
- breast cancer (1)
- bridging (1)
- brucei (1)
- cadherins (1)
- cancer (1)
- cancer care (1)
- candidate genes (1)
- cardiac dysfunction (1)
- cardiac hypertrophy (1)
- cardiac rehabilitation (1)
- cardiogenetics (1)
- cardiovascular munster procam (1)
- caregiver burden (1)
- cell (1)
- cerebral ischemia (1)
- chemistry (1)
- chemotherapy (1)
- chip-seq (1)
- clinical skills (1)
- cornea verticillata (1)
- coronary artery disease (1)
- crithidia fasciulata (1)
- cryptogenic stroke (1)
- damage (1)
- decreasing autonomy (1)
- depression (1)
- diabetic mouse (1)
- e-Learning (1)
- echocardiography (1)
- ejection fraction (1)
- elements (1)
- enzyme replacement therapy (1)
- epigenetics (1)
- exercise training (1)
- expression signature (1)
- extinction (1)
- feasibility (1)
- female (1)
- foci (1)
- frailty (1)
- functional status (1)
- gender (1)
- genetic interaction networks (1)
- genetic variants (1)
- genetics (1)
- genome (1)
- haplogroups (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hearing loss (1)
- heart failure (1)
- heterozygote (1)
- high denisty lipoprotein (1)
- histone H2AX (1)
- home-based-rehabilitation (1)
- hormone-related protein (1)
- human ectoparasite (1)
- humans (1)
- immune check inhibitor (1)
- in vivo (1)
- in vivo imaging (1)
- individual radiosensitivity (1)
- infection detection (1)
- informal caregiving (1)
- inherited metabolic disorders (1)
- left ventricular mass (1)
- leishmaniasis (1)
- low-molecular heparin (1)
- luminescence (1)
- lymph node (1)
- lysosomal storage disorder (1)
- mRNA (1)
- mammographic density (1)
- medical device training (1)
- mesoscopics (1)
- metabolism (1)
- middle aged (1)
- migration (1)
- mitochondria (1)
- molecular diagnostics (1)
- monoamine oxidase A (1)
- multicentric (1)
- multiple diseases (1)
- neck cancer (1)
- neurodevelopmental disorders / genetics (1)
- neuroprotection (1)
- neurorepair (1)
- nitrate and thyroid carcinogenesis (1)
- non-interventional (1)
- old patients (1)
- oral mucositis (1)
- oral squamous cell carcinoma (1)
- oropharyngeal carcinoma (1)
- orylation (1)
- outcomes research (1)
- outreach (1)
- oxidative stress (1)
- pN1 (1)
- parathyroid carcinoma (1)
- patient access (1)
- pediatric thyroid cancer after Chernobyl and Fukushima (1)
- pembrolizumab (1)
- phospholipid fatty acids (1)
- phosphorylation (1)
- physical activity (1)
- placebo-controlled trial (1)
- point-of-care echocardiography (1)
- polycyclic aromatic hydrocarbons (1)
- polymorphism (1)
- population (1)
- postoperative bleeding (1)
- precision oncology (1)
- progression-free survival (1)
- psychological interventions (1)
- psychological support (1)
- purification (1)
- quality of life (1)
- quality of life (QoL) (1)
- radiosensitivity (1)
- randomized controlled-trial (1)
- real world data (1)
- rectal cancer (1)
- redox (1)
- renal dysfunction (1)
- renal fibrosis (1)
- repair (1)
- repeated surgery (1)
- resection (1)
- residual cardiovascular risk (1)
- rising incidence of thyroid cancer (1)
- sarcoma (1)
- scientific guidelines (1)
- screening and overdiagnosis (1)
- secondary prevention (1)
- selection (1)
- septal hypertrophy (1)
- small vessel disease (1)
- socioeconomic status (1)
- stroke unit (1)
- subtypes (1)
- superconductivity (1)
- surgery (1)
- susceptibility (1)
- susceptibility alleles (1)
- symptom-specific treatment (1)
- system (1)
- systolic dysfunction (1)
- targeted gene panel (1)
- tele-medicine (1)
- term fenofibrate therapy (1)
- therapeutic options (1)
- thromboembolism (1)
- topological insulators (1)
- trabectedin (1)
- translational research (1)
- triglyceride-rich lipoproteins (1)
- troponin (1)
- trypanosoma cruzi (1)
- tuberculosis (1)
- tumor subtypes (1)
- type 2 diabetes (1)
- type-2 diabetes mellitus (1)
- urinary protein excretion (1)
- variants (1)
- vascular dementia (1)
- vertigo (1)
- whole exome sequencing (1)
- young patients (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Medizinische Klinik und Poliklinik I (11)
- Institut für Humangenetik (9)
- Neurologische Klinik und Poliklinik (7)
- Institut für Klinische Epidemiologie und Biometrie (4)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (3)
- Medizinische Klinik und Poliklinik II (3)
- Institut für Mathematik (2)
- Institut für Pharmazie und Lebensmittelchemie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
Sonstige beteiligte Institutionen
Unique features of a global human ectoparasite identified through sequencing of the bed bug genome
(2016)
The bed bug, Cimex lectularius, has re-established itself as a ubiquitous human ectoparasite throughout much of the world during the past two decades. This global resurgence is likely linked to increased international travel and commerce in addition to widespread insecticide resistance. Analyses of the C. lectularius sequenced genome (650 Mb) and 14,220 predicted protein-coding genes provide a comprehensive representation of genes that are linked to traumatic insemination, a reduced chemosensory repertoire of genes related to obligate hematophagy, host–symbiont interactions, and several mechanisms of insecticide resistance. In addition, we document the presence of multiple putative lateral gene transfer events. Genome sequencing and annotation establish a solid foundation for future research on mechanisms of insecticide resistance, human–bed bug and symbiont–bed bug associations, and unique features of bed bug biology that contribute to the unprecedented success of C. lectularius as a human ectoparasite.
Background:
In recent years attention has focused on \(\gamma\)H2AX as a very sensitive double strand break indicator. It has been suggested that \(\gamma\)H2AX might be able to predict individual radiosensitivity. Our aim was to study the induction and repair of DNA double strand breaks labelled by \(\gamma\)H2AX in a large cohort.
Methods:
In a prospective study lymphocytes of 136 rectal cancer (RC) patients and 59 healthy individuals were ex vivo irradiated (IR) and initial DNA damage was compared to remaining DNA damage after 2 Gy and 24 hours repair time and preexisting DNA damage in unirradiated lymphocytes. Lymphocytes were immunostained with anti-\(\gamma\)H2AX antibodies and microscopic images with an extended depth of field were acquired. \(\gamma\)H2AX foci counting was performed using a semi-automatic image analysis software.
Results:
Distinct increased values of preexisting and remaining \(\gamma\)H2AX foci in the group of RC patients were found compared to the healthy individuals. Additionally there are clear differences within the groups and there are outliers in about 12% of the RC patients after ex vivo IR.
Conclusions:
The \(\gamma\)H2AX assay has the capability to identify a group of outliers which are most probably patients with increased radiosensitivity having the highest risk of suffering radiotherapy-related late sequelae.
Background
BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).
Methods
We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.
Results
Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12).
Conclusions
On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.
Background
Troponin elevation is common in ischemic stroke (IS) patients. The pathomechanisms involved are incompletely understood and comprise coronary and non-coronary causes, e.g. autonomic dysfunction. We investigated determinants of troponin elevation in acute IS patients including markers of autonomic dysfunction, assessed by heart rate variability (HRV) time domain variables.
Methods
Data were collected within the Stroke Induced Cardiac FAILure (SICFAIL) cohort study. IS patients admitted to the Department of Neurology, Würzburg University Hospital, underwent baseline investigation including cardiac history, physical examination, echocardiography, and blood sampling. Four HRV time domain variables were calculated in patients undergoing electrocardiographic Holter monitoring. Multivariable logistic regression with corresponding odds ratios (OR) and 95% confidence intervals (CI) was used to investigate the determinants of high-sensitive troponin T (hs-TnT) levels ≥14 ng/L.
Results
We report results from 543 IS patients recruited between 01/2014–02/2017. Of those, 203 (37%) had hs-TnT ≥14 ng/L, which was independently associated with older age (OR per year 1.05; 95% CI 1.02–1.08), male sex (OR 2.65; 95% CI 1.54–4.58), decreasing estimated glomerular filtration rate (OR per 10 mL/min/1.73 m2 0.71; 95% CI 0.61–0.84), systolic dysfunction (OR 2.79; 95% CI 1.22–6.37), diastolic dysfunction (OR 2.29; 95% CI 1.29–4.02), atrial fibrillation (OR 2.30; 95% CI 1.25–4.23), and increasing levels of C-reactive protein (OR 1.48 per log unit; 95% CI 1.22–1.79). We did not identify an independent association of troponin elevation with the investigated HRV variables.
Conclusion
Cardiac dysfunction and elevated C-reactive protein, but not a reduced HRV as surrogate of autonomic dysfunction, were associated with increased hs-TnT levels in IS patients independent of established cardiovascular risk factors.
Epigenetic mechanisms have been proposed to mediate fear extinction in animal models. Here, MAOA methylation was analyzed via direct sequencing of sodium bisulfite-treated DNA extracted from blood cells before and after a 2-week exposure therapy in a sample of n = 28 female patients with acrophobia as well as in n = 28 matched healthy female controls. Clinical response was measured using the Acrophobia Questionnaire and the Attitude Towards Heights Questionnaire. The functional relevance of altered MAOA methylation was investigated by luciferase-based reporter gene assays. MAOA methylation was found to be significantly decreased in patients with acrophobia compared with healthy controls. Furthermore, MAOA methylation levels were shown to significantly increase after treatment and correlate with treatment response as reflected by decreasing Acrophobia Questionnaire/Attitude Towards Heights Questionnaire scores. Functional analyses revealed decreased reporter gene activity in presence of methylated compared with unmethylated pCpGfree_MAOA reporter gene vector constructs. The present proof-of-concept psychotherapy-epigenetic study for the first time suggests functional MAOA methylation changes as a potential epigenetic correlate of treatment response in acrophobia and fosters further investigation into the notion of epigenetic mechanisms underlying fear extinction.
Background
Fabry Disease (FD) is an X-linked hereditary lysosomal storage disorder which leads to a multisystemic intralysosomal accumulation of globotriaosylceramid (Gb3). Besides prominent renal and cardiac organ involvement, patients commonly complain about vestibulocochlear symptoms like high-frequency hearing loss, tinnitus and vertigo. However, comprehensive data especially on vertigo remain scarce. The aim of this study was to examine the prevalence and characteristics of vertigo and hearing loss in patients with FD, depending on renal and cardiac parameters and get hints about the site and the pattern of the lesions.
Methods
Single-center study with 57 FD patients. Every patient underwent an oto-rhino-laryngological examination as well as videonystagmography and vestibular evoked myogenic potentials (VEMPs) and audiological measurements using pure tone audiometry and auditory brainstem response audiometry (ABR). Renal function was measured by eGFR, cardiac impairment was graduated by NYHA class.
Results
More than one out of three patients (35.1%) complained about hearing loss, 54.4% about vertigo and 28.1% about both symptom. In 74% a sensorineural hearing loss of at least 25 dB was found, ABR could exclude any retrocochlear lesion. Caloric testing showed abnormal values in 71.9%, VEMPs were pathological in 68%. A correlation between the side or the shape of hearing loss and pathological vestibular testing could not be revealed.
Conclusions
Hearing loss and vertigo show a high prevalence in FD. While hearing loss seems due to a cochlear lesion, peripheral vestibular as well as central nervous pathologies cause vertigo. Thus, both the site of lesion and the pathophysiological patterns seem to differ.
We synthesized new pyrene derivatives with strong bis(para ‐methoxyphenyl)amine donors at the 2,7‐positions and n ‐azaacene acceptors at the K‐region of pyrene. The compounds possess a strong intramolecular charge transfer, leading to unusual properties such as emission in the red to NIR region (700 nm), which has not been reported before for monomeric pyrenes. Detailed photophysical studies reveal very long intrinsic lifetimes of >100 ns for the new compounds, which is typical for 2,7‐substituted pyrenes but not for K‐region substituted pyrenes. The incorporation of strong donors and acceptors leads to very low reduction and oxidation potentials, and spectroelectrochemical studies show that the compounds are on the borderline between localized Robin‐Day class‐II and delocalized Robin‐Day class‐III species.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive autonomy loss and need for care. This does not only affect patients themselves, but also the patients’ informal caregivers (CGs) in their health, personal and professional lives. The big efforts of this multi-center study were not only to evaluate the caregivers' burden and to identify its predictors, but it also should provide a specific understanding of the needs of ALS patients' CGs and fill the gap of knowledge on their personal and work lives. Using standardized questionnaires, primary data from patients and their main informal CGs (n = 249) were collected. Patients' functional status and disease severity were evaluated using the Barthel Index, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and the King’s Stages for ALS. The caregivers' burden was recorded by the Zarit Burden Interview (ZBI). Comorbid anxiety and depression of caregivers were assessed by the Hospital Anxiety and Depression Scale. Additionally, the EuroQol Five Dimension Five Level Scale evaluated their health-related quality of life. The caregivers' burden was high (mean ZBI = 26/88, 0 = no burden, ≥24 = highly burdened) and correlated with patients' functional status (r\(_p\) = −0.555, p < 0.001, n = 242). It was influenced by the CGs' own mental health issues due to caregiving (+11.36, 95% CI [6.84; 15.87], p < 0.001), patients' wheelchair dependency (+9.30, 95% CI [5.94; 12.66], p < 0.001) and was interrelated with the CGs' depression (r\(_p\) = 0.627, p < 0.001, n = 234), anxiety (r\(_p\) = 0.550, p < 0.001, n = 234), and poorer physical condition (r\(_p\) = −0.362, p < 0.001, n = 237). Moreover, female CGs showed symptoms of anxiety more often, which also correlated with the patients' impairment in daily routine (r\(_s\) = −0.280, p < 0.001, n = 169). As increasing disease severity, along with decreasing autonomy, was the main predictor of caregiver burden and showed to create relevant (negative) implications on CGs' lives, patient care and supportive therapies should address this issue. Moreover, in order to preserve the mental and physical health of the CGs, new concepts of care have to focus on both, on not only patients but also their CGs and gender-associated specific issues. As caregiving in ALS also significantly influences the socioeconomic status by restrictions in CGs' work lives and income, and the main reported needs being lack of psychological support and a high bureaucracy, the situation of CGs needs more attention. Apart from their own multi-disciplinary medical and psychological care, more support in care and patient management issues is required.
Inherited cardiomyopathies are characterized by clinical and genetic heterogeneity that challenge genetic diagnostics. In this study, we examined the diagnostic benefit of exome data compared to targeted gene panel analyses, and we propose new candidate genes. We performed exome sequencing in a cohort of 61 consecutive patients with a diagnosis of cardiomyopathy or primary arrhythmia, and we analyzed the data following a stepwise approach. Overall, in 64% of patients, a variant of interest (VOI) was detected. The detection rate in the main sub-cohort consisting of patients with dilated cardiomyopathy (DCM) was much higher than previously reported (25/36; 69%). The majority of VOIs were found in disease-specific panels, while a further analysis of an extended panel and exome data led to an additional diagnostic yield of 13% and 5%, respectively. Exome data analysis also detected variants in candidate genes whose functional profile suggested a probable pathogenetic role, the strongest candidate being a truncating variant in STK38. In conclusion, although the diagnostic yield of gene panels is acceptable for routine diagnostics, the genetic heterogeneity of cardiomyopathies and the presence of still-unknown causes favor exome sequencing, which enables the detection of interesting phenotype–genotype correlations, as well as the identification of novel candidate genes.
Improving quality of life (QoL) is central to amyotrophic lateral sclerosis (ALS) treatment. This Germany-wide, multicenter cross-sectional study analyses the impact of different symptom-specific treatments and ALS variants on QoL. Health-related QoL (HRQoL) in 325 ALS patients was assessed using the Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) and EuroQol Five Dimension Five Level Scale (EQ-5D-5L), together with disease severity (captured by the revised ALS Functional Rating Scale (ALSFRS-R)) and the current care and therapies used by our cohort. At inclusion, the mean ALSAQ-5 total score was 56.93 (max. 100, best = 0) with a better QoL associated with a less severe disease status (β = −1.96 per increase of one point in the ALSFRS-R score, p < 0.001). “Limb-onset” ALS (lALS) was associated with a better QoL than “bulbar-onset” ALS (bALS) (mean ALSAQ-5 total score 55.46 versus 60.99, p = 0.040). Moreover, with the ALSFRS-R as a covariate, using a mobility aid (β = −7.60, p = 0.001), being tracheostomized (β = −14.80, p = 0.004) and using non-invasive ventilation (β = −5.71, p = 0.030) were associated with an improved QoL, compared to those at the same disease stage who did not use these aids. In contrast, antidepressant intake (β = 5.95, p = 0.007), and increasing age (β = 0.18, p = 0.023) were predictors of worse QoL. Our results showed that the ALSAQ-5 was better-suited for ALS patients than the EQ-5D-5L. Further, the early and symptom-specific clinical management and supply of assistive devices can significantly improve the individual HRQoL of ALS patients. Appropriate QoL questionnaires are needed to monitor the impact of treatment to provide the best possible and individualized care.